Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Gene Therapy|June 6, 1998
Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector--potential glioblastoma targetingE A McKie, D I Graham, S M BrownJournal of Virology|November 26, 1997
The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34S M Brown, A R MacLean, E A McKie, et al.Neuropathology and Applied Neurobiology|November 20, 1998
Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapyE A McKie, S M Brown, A R MacLean, et al.The Journal of General Virology|April 1, 1994
Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial systemE A McKie, R G Hope, S M Brown, et al.Journal of Virology|February 1, 1995
The transcripts from the sequences flanking the short component of Marek's disease virus during latent infection form a unique family of 3'-coterminal RNAsE A McKie, E Ubukata, S Hasegawa, et al.British Journal of Cancer|September 1, 1996
Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapyE A McKie, A R MacLean, A D Lewis, et al.The Journal of General Virology|February 1, 1995
Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye modelJ G Spivack, M U Fareed, T Valyi-Nagy, et al.Pageof 1